J&J Begins Human Trials of Its One-Dose COVID-19 Vaccine

After data demonstrated Johnson and Johnson’s (J&J) one-dose vaccine offered significant protection against COVID-19 in monkeys, the pharmaceutical giant started human trials on July 30. The initial trial includes 1,000 adults in both the United States and Belgium. If these data show safety and efficacy, the company plans to begin large-scale human trials in September. Testing on a two-shot vaccine is also underway. J&J has received more than $450 million from the federal government to support its COVID-19 vaccine development efforts. Read more here.